Hodgkin’s lymphoma is a type of cancer affecting the body’s infection-fighting system. While the diagnosis can be overwhelming, understanding the treatment options—from long-established chemotherapy to cutting-edge therapies being tested in clinical trials—helps patients and families navigate the journey ahead with greater confidence and hope.

Understanding Your Treatment Path: What to Expect with Hodgkin’s Disease

When someone receives a diagnosis of Hodgkin’s lymphoma, one of the first questions that comes to mind is: what happens next? The good news is that this type of cancer responds remarkably well to treatment, with cure rates reaching approximately 80% or higher in many cases.^[4] Treatment decisions depend on several important factors, including the stage of the disease, which areas of the body are affected, whether certain symptoms are present, the patient’s age, and overall health.^[1][13]

The main goal of treatment is not just to eliminate cancer cells, but also to help patients maintain or improve their quality of life during and after therapy. Medical teams consider multiple aspects when planning treatment: they look at where the lymphoma started, whether it has spread to other lymph nodes or organs, and whether the patient experiences what doctors call B symptoms—a specific set of whole-body symptoms including fever, significant weight loss, and drenching night sweats that can indicate more active disease.^[2][13]

Hodgkin’s lymphoma most commonly begins in lymph nodes in the neck or chest area, though it can also develop in lymph nodes under the arms, in the groin, abdomen, or pelvis.^[15] The disease is divided into two main categories: classical Hodgkin lymphoma, which accounts for about 95% of cases, and nodular lymphocyte-predominant Hodgkin lymphoma, which is less common.^[4] Each type may require a slightly different treatment approach, which is why accurate diagnosis through biopsy and staging is so crucial before treatment begins.

Standard Treatment Approaches: The Foundation of Hodgkin’s Lymphoma Care

The backbone of Hodgkin’s lymphoma treatment consists of chemotherapy—the use of powerful drugs to kill cancer cells—often combined with radiation therapy, which uses high-energy rays to destroy cancer cells in specific areas of the body.^[1][11] These treatments have been refined over decades and form the standard of care recommended by medical societies and cancer treatment guidelines worldwide.

Chemotherapy for Hodgkin’s lymphoma typically involves a combination of several different drugs given together. This approach is more effective than using a single drug because different medications attack cancer cells in different ways. One of the most commonly used chemotherapy combinations is called ABVD, which stands for the four drugs it contains: doxorubicin (also called Adriamycin), bleomycin, vinblastine, and dacarbazine.^[9][13] These drugs are usually given through a vein in cycles, with treatment periods followed by rest periods to allow the body to recover.

The duration of chemotherapy depends on the stage and characteristics of the lymphoma. Early-stage disease might require fewer cycles—perhaps two to four cycles—while more advanced disease typically needs six to eight cycles or more. Each cycle usually lasts several weeks, meaning the entire course of chemotherapy can span several months.^[9][12]

Radiation therapy may be used after chemotherapy, especially for early-stage disease or when there are large masses of lymphoma in the chest or other areas. The radiation is carefully directed at the affected lymph nodes and surrounding areas, aiming to destroy any remaining cancer cells while minimizing damage to healthy tissue.^[10][12] Modern radiation techniques have become much more precise, reducing the dose and the area treated compared to older approaches, which helps minimize long-term side effects.

For patients whose disease is more advanced or has certain high-risk features, doctors may recommend more intensive chemotherapy regimens. Some of these include combinations with names like BEACOPP or Stanford V, which use different drugs or higher doses to attack the cancer more aggressively.^[9][11] While these regimens may increase the chance of eliminating the cancer, they can also cause more severe side effects, so the decision to use them involves carefully weighing risks and benefits for each individual patient.

Beyond chemotherapy and radiation, standard treatment increasingly includes other approaches. Targeted therapy refers to drugs that specifically attack certain features of cancer cells, causing less harm to normal cells than traditional chemotherapy. Immunotherapy works by helping the patient’s own immune system recognize and destroy cancer cells.^[3][12] These newer treatments have become part of standard care in certain situations, particularly when the disease returns after initial treatment or doesn’t respond adequately to first-line therapy.

When Initial Treatment Isn’t Enough: Options for Relapsed or Refractory Disease

Sometimes, Hodgkin’s lymphoma returns after initial successful treatment—a situation called relapse or recurrence. In other cases, the disease doesn’t respond adequately to the first treatment, which doctors call refractory disease.^[13] While this is disappointing and concerning for patients and families, effective treatment options still exist, and many people with relapsed or refractory Hodgkin’s lymphoma can still achieve remission.

For patients in this situation, one important option is high-dose chemotherapy followed by stem cell transplantation. This approach uses very high doses of chemotherapy to kill cancer cells more effectively than standard doses, but these high doses would also destroy the bone marrow, which produces blood cells. To rescue the bone marrow, stem cells—immature blood cells that can develop into all types of blood cells—are collected from the patient before the high-dose chemotherapy and then returned to the body afterward. These stem cells travel to the bone marrow and begin producing new, healthy blood cells.^[3][10][12]

This procedure, often called an autologous stem cell transplant (because the patient’s own stem cells are used), requires hospitalization and careful monitoring but has helped cure many patients whose lymphoma returned after initial treatment. Recovery from transplant takes several months, during which the patient must take precautions against infection because their immune system is rebuilding.

Breaking New Ground: Innovative Therapies in Clinical Trials

While standard treatments work well for most patients with Hodgkin’s lymphoma, researchers continuously work to develop new therapies that are more effective, cause fewer side effects, or work better for patients whose disease doesn’t respond to standard treatment. These new approaches are tested in clinical trials—carefully designed research studies that evaluate new treatments in patients.

Clinical trials follow a structured process divided into phases. Phase I trials focus primarily on safety, determining what dose of a new treatment can be given safely and what side effects might occur. These trials usually involve small numbers of patients. Phase II trials test whether the treatment actually works against the cancer and continue to monitor safety. Phase III trials compare the new treatment to the current standard treatment to see if it’s better, as effective with fewer side effects, or works differently in important ways.^[11]

One area of intense research involves checkpoint inhibitors, a type of immunotherapy that works by blocking proteins that prevent the immune system from attacking cancer cells. Two such drugs, nivolumab and pembrolizumab, have shown promising results in clinical trials for Hodgkin’s lymphoma, particularly for patients whose disease has relapsed or is refractory to other treatments.^[9][14] These drugs block a protein called PD-1 on immune cells, which essentially takes the brakes off the immune system and allows it to attack the lymphoma cells more effectively.

Another targeted drug that has emerged from clinical trials is brentuximab vedotin. This medication is an antibody-drug conjugate, which means it combines an antibody that recognizes a specific protein on Hodgkin’s lymphoma cells (called CD30) with a chemotherapy drug. The antibody acts like a guided missile, delivering the chemotherapy directly to the cancer cells while sparing most normal cells.^[9][12][14] Brentuximab vedotin has been studied in multiple clinical trials and is now used as part of standard treatment in certain situations, particularly for relapsed disease.

Clinical trials are being conducted at major cancer centers around the world, including in the United States, Europe, and other regions. Eligibility for clinical trials depends on many factors, including the stage and type of lymphoma, previous treatments received, and the patient’s overall health.^[11] Patients interested in clinical trials should discuss this option with their oncologist, who can help determine whether any appropriate trials are available.

Researchers are also investigating novel approaches such as CAR T-cell therapy, where a patient’s own immune cells are collected, genetically modified in the laboratory to better recognize and attack lymphoma cells, and then returned to the patient. While CAR T-cell therapy has shown dramatic results in some other types of lymphoma, research is ongoing to determine its role in Hodgkin’s lymphoma.^[14] Other areas of investigation include new combinations of existing drugs, better ways to predict which patients will respond to which treatments, and strategies to reduce long-term side effects while maintaining treatment effectiveness.

Most common treatment methods

• Chemotherapy
  • ABVD combination (doxorubicin, bleomycin, vinblastine, dacarbazine) is one of the most commonly used chemotherapy regimens
  • BEACOPP and Stanford V are more intensive regimens for advanced or high-risk disease
  • High-dose chemotherapy followed by stem cell transplantation for relapsed or refractory disease
  • Treatment is given in cycles over several months, with rest periods between cycles
• Radiation therapy
  • Uses high-energy rays to destroy cancer cells in specific areas
  • Often given after chemotherapy for early-stage disease
  • Modern techniques deliver more precise radiation to minimize side effects
  • Particularly useful for treating large masses in the chest or other areas
• Targeted therapy
  • Brentuximab vedotin: an antibody-drug conjugate that delivers chemotherapy directly to CD30-positive lymphoma cells
  • Attacks specific features of cancer cells while sparing normal cells
  • Used particularly for relapsed or refractory disease
• Immunotherapy
  • Checkpoint inhibitors like nivolumab and pembrolizumab block PD-1 protein, allowing the immune system to attack cancer cells
  • Helps the patient’s own immune system recognize and destroy lymphoma cells
  • Showing promising results in clinical trials for relapsed or refractory disease
• Stem cell transplantation
  • Autologous transplant uses the patient’s own stem cells collected before high-dose chemotherapy
  • Allows use of very high chemotherapy doses to kill cancer cells
  • Important option for patients whose disease has relapsed or is refractory to standard treatment
  • Requires hospitalization and several months of recovery

Life After Treatment: Follow-Up Care and Long-Term Considerations

Completing treatment for Hodgkin’s lymphoma is a major milestone, but it’s not the end of the healthcare journey. Because the disease can sometimes return and because treatments can cause effects that appear years later, ongoing follow-up care is essential. After finishing treatment, patients typically see their oncologist regularly—often every few months at first, then less frequently over time.^[21][22]

These follow-up visits serve multiple purposes. The doctor will check for any signs that the lymphoma might be returning, monitor for late effects of treatment, and help manage any ongoing symptoms or concerns. Follow-up may include physical examinations, blood tests, and sometimes imaging scans like CT scans, depending on individual risk factors and how long it’s been since treatment ended.^[18][21]

Many cancer centers now use a survivorship care plan, which is a personalized document that summarizes the treatments received, outlines potential late effects to watch for, and provides a schedule for recommended follow-up tests and screenings.^[19][24] This plan helps both the oncologist and the patient’s primary care doctor coordinate care and ensure that nothing important is missed.

Many survivors experience emotional and psychological challenges during and after treatment. It’s normal to feel anxious about the possibility of the cancer returning, to struggle with fatigue or other lingering physical effects, or to find it difficult to return to “normal” life.^[17][20] Support services, including counseling, support groups, and survivorship clinics, can help people navigate these challenges. Some patients find it helpful to connect with others who have been through similar experiences.

Maintaining overall health becomes particularly important for Hodgkin’s lymphoma survivors. A balanced diet rich in fruits, vegetables, whole grains, and lean proteins supports the body’s recovery and ongoing health.^[23][24] Regular physical activity, as tolerated, helps combat fatigue, maintains strength and cardiovascular health, and improves mood. Even gentle activities like walking can make a significant difference. Survivors should avoid tobacco in all forms, limit alcohol consumption, maintain a healthy weight, and practice good sun protection, as these measures help reduce the risk of second cancers and other health problems.

Fertility is an important concern for many younger patients with Hodgkin’s lymphoma. Both chemotherapy and radiation to certain areas can affect fertility—the ability to have biological children. The risk varies depending on the specific treatments used, doses given, and the patient’s age at treatment.^[6][12] It’s important to discuss fertility concerns with the medical team before starting treatment, when possible. Options for preserving fertility may include freezing eggs or sperm, medications to protect the ovaries during chemotherapy, or other strategies. For those whose fertility is affected by treatment, adoption, egg or sperm donation, and other options for building a family remain available.